Bias Is Everywhere

Editor's Note: This article is a professional perspective written to stimulate thoughtful discussion about bias in science and medicine. It reflects observations across academic medicine, government health systems, and industry-adjacent medical education, and is intended to promote transparency, intellectual honesty, and patient-centered care.

The Uncomfortable Truth

Bias in medicine is most often discussed through a single lens: industry bias. It is a hot topic—and an important one. But focusing on it exclusively risks missing a broader, more consequential truth:

Bias exists everywhere in medicine, including in places that claim moral superiority or immunity from influence.

This essay is not an indictment of industry. Nor is it an attack on academia, government systems, or clinicians. It is a call for intellectual honesty—because when bias goes unacknowledged or is selectively weaponized, patients suffer.

Innovation, Influence, and Reality

How Medicine Evolves

Medicine evolves through collaboration. Scientific progress requires relationships among researchers, clinicians, educators, institutions, regulators, entrepreneurs, investors, and yes—pharmaceutical and device companies. These relationships require funding. There is no way around that.

The presence of money does not inherently corrupt science or medicine. But wherever money, reputation, or institutional survival are involved, bias becomes possible. That reality demands transparency and regulation—not denial.

Ironically, in medicine there is often more suspicion directed at those who openly disclose relationships than at those who claim to have none.
That imbalance deserves scrutiny.

Industry Bias and the Sunshine Act

The Physician Payments Sunshine Act (2010) was designed to promote transparency by publicly disclosing financial relationships between physicians and industry. Its goal is visibility—not judgment.

Transparency is essential. But transparency alone does not provide balance or context. It does not acknowledge that these relationships are often necessary for innovation, education, and translation of science into practice.

Nor does it address the uncomfortable truth: The absence of disclosed relationships does not equal the absence of influence.

"No Disclosures" Bias

In continuing medical education (CME), speakers are required to disclose industry relationships. Having disclosures is not inherently problematic—it is expected. But in some circles, declaring "No Disclosures" has become a badge of moral superiority.

Example 1: The Guideline Writer

At a national cardiology meeting, a cholesterol guideline author publicly contrasted their "No Disclosures" status with another speaker's extensive disclosures, implying ethical superiority. Later, in private conversation, the same individual emphasized their lack of disclosed relationships as evidence of independence.

What was left unsaid: This guideline writer had previously been invited to speak at an educational lecture funded through an unrestricted educational grant supported by a pharmaceutical company with a branded drug in that disease space.

The lecture was labeled CME. The funding pathway obscured the influence. The relationship was real, but invisible.

This was not freedom from bias—it was bias disguised as purity.

Example 2: Academic CME and Institutional Blind Spots

Many prominent academic institutions prohibit their faculty from engaging directly with industry. Speakers routinely declare "No Disclosures."

Yet the conferences themselves are often heavily funded by industry, philanthropies, and global donors. The institution benefits financially. The faculty speak on its behalf.

The result? An audience left with the impression that no bias exists—when influence is simply institutional rather than individual.

Ivory Tower Bias

Pay-to-Play Without Disclosure

Some large academic centers restrict industry access unless companies contribute financially to institutional education funds. The money supports GME and CME—but the relationship is rarely disclosed at the podium.

Smaller training programs, lacking such resources, often adopt a culture of strict exclusion to "keep up appearances." The unintended consequence is educational deprivation.

Trainees and community physicians are denied exposure to expert-level nuance—not because it is unethical, but because it might look unethical.

Bias toward appearance replaces bias toward education.

Government Bias

When Cost Becomes the Primary Driver

Government healthcare systems face unique constraints. Cost matters. Stewardship matters. But when cost becomes the primary driver of clinical decision-making, bias can quietly erode care.

Off-Label Prescribing for Cost Alone

Off-label prescribing can be appropriate—but routine off-label use driven solely by cost-saving, without supporting evidence, is poor medicine.

One example involved altering the FDA-approved dosing of ezetimibe to reduce cost, despite no peer-reviewed evidence supporting equivalent outcomes. The rationale was financial—not scientific.

Inferior Guidelines in the Name of Savings

The VA/DOD cholesterol guideline once proposed LDL-C targets far above global standards at a time when superior therapy was well established. The primary distinction? Cost.

Such deviations risk returning entire populations to inferior eras of care—not because science demanded it, but because budgets did.

Weaponizing Discordance to Deny Care

In lipidology, discordance—where LDL-C underestimates atherogenic particle burden—is a well-established phenomenon. Risk tracks with ApoB, not LDL-C, especially when triglycerides are elevated.

Yet discordance has been used by payers as justification to deny therapies like icosapent ethyl in patients who clearly meet FDA indications.

This is not ignorance. It is selective interpretation—a bias that harms the highest-risk patients.

Evidence Hierarchy Bias: When Two Opinions Don't Carry Equal Weight

Science is not a democracy. Observational data, opinion pieces, and randomized double-blind trials are often presented as if they carry equivalent weight. This is evidence hierarchy bias—and it harms patients.

The 2013 Controversy

In 2013, a publication in a respected journal claimed to present "the other side" of the statin debate. It presented observational data suggesting widespread side effects from statin therapy. The message was loud, alarming, and widely publicized.

The problem? It was presented as scientifically robust, despite being based on observational research—not a rigorous trial design.

The 2026 Evidence

In February 2026, a comprehensive meta-analysis published in the Lancet examined 19 randomized, double-blind trials involving 123,940 patients. The goal was to test all 66 side effects that had been attributed to statins in prior work.

Result: 64 of 66 side effects were not caused by statins.

This provided robust safety data to refute that 2013 publication beyond reasonable doubt.

Why This Matters: The Hierarchy Deserves Respect

The 2013 observational study and the 2026 randomized trial are not equivalent. They never were. Yet for more than a decade, both received similar attention and credibility in public discourse, medical practice, and policy discussions.

As one expert commentary framed it:

"The public needs to understand the difference between observational research, opinions, and randomised double-blind trials all badged under the umbrella of science. Science isn't about headlines, shouting the loudest, but meticulous methodology and rigour."

This is the essence of evidence hierarchy bias: giving equivalent credibility to dramatically different levels of scientific evidence.

What Patients Should Know

When your physician or a policy maker presents medical evidence, ask the right question:

"What level of evidence supports this claim?"

Is it a rigorous randomized controlled trial with thousands of patients? Or is it observational data? An editorial? A single case report?

Meticulous methodology and robust evidence should prevail.

Bias Is Not the Enemy—Unacknowledged Bias Is

Honesty About Influence

I am not immune to bias. No clinician is.

The goal is not purity. It is awareness, disclosure, and correction when bias threatens patient care.

• Industry bias exists.
• Academic bias exists.
• Government bias exists.
• So does personal, intellectual, and cultural bias.

Pretending otherwise does not protect patients—it endangers them.

Why This Matters: The Bottom Line

Bias that delays innovation, suppresses nuance, or justifies inferior care under the guise of virtue is not ethical—it is harmful.

Progress in medicine requires honesty about influence, not denial of it. The question is not whether bias exists, but whether we recognize it, regulate it, and prevent it from overriding evidence and judgment.

Patients deserve nothing less than transparency, rigor, and a commitment to evidence-based care—regardless of where bias might hide.

Disclaimer: This article represents the professional perspective of the author and is intended to stimulate discussion about bias in medicine and science. It does not represent endorsement or criticism of any specific organization, institution, or individual. All readers are encouraged to apply critical thinking to all sources of medical information, regardless of origin.